176 related articles for article (PubMed ID: 9413088)
1. Effects of carbohydrate modification of Quillaja saponaria Molina QH-B fraction on adjuvant activity, cholesterol-binding capacity and toxicity.
Rönnberg B; Fekadu M; Behboudi S; Kenne L; Morein B
Vaccine; 1997 Dec; 15(17-18):1820-6. PubMed ID: 9413088
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant activity of non-toxic Quillaja saponaria Molina components for use in ISCOM matrix.
Rönnberg B; Fekadu M; Morein B
Vaccine; 1995 Oct; 13(14):1375-82. PubMed ID: 8585296
[TBL] [Abstract][Full Text] [Related]
3. In vivo and in vitro induction of IL-6 by Quillaja saponaria molina triterpenoid formulations.
Behboudi S; Morein B; Villacres-Eriksson M
Cytokine; 1997 Sep; 9(9):682-7. PubMed ID: 9325017
[TBL] [Abstract][Full Text] [Related]
4. In vitro activation of antigen-presenting cells (APC) by defined composition of Quillaja saponaria Molina triterpenoids.
Behboudi S; Morein B; Villacres-Eriksson M
Clin Exp Immunol; 1996 Jul; 105(1):26-30. PubMed ID: 8697631
[TBL] [Abstract][Full Text] [Related]
5. Isolation and quantification of Quillaja saponaria Molina saponins and lipids in iscom-matrix and iscoms.
Behboudi S; Morein B; Rönnberg B
Vaccine; 1995 Dec; 13(17):1690-6. PubMed ID: 8719521
[TBL] [Abstract][Full Text] [Related]
6. Novel ISCOMs from Quillaja brasiliensis saponins induce mucosal and systemic antibody production, T-cell responses and improved antigen uptake.
Cibulski SP; Mourglia-Ettlin G; Teixeira TF; Quirici L; Roehe PM; Ferreira F; Silveira F
Vaccine; 2016 Feb; 34(9):1162-71. PubMed ID: 26826546
[TBL] [Abstract][Full Text] [Related]
7. Saponin Interactions with Model Membrane Systems - Langmuir Monolayer Studies, Hemolysis and Formation of ISCOMs.
de Groot C; Müller-Goymann CC
Planta Med; 2016 Dec; 82(18):1496-1512. PubMed ID: 27760443
[TBL] [Abstract][Full Text] [Related]
8. Saponins from Quillaja saponaria Molina: isolation, characterization and ability to form immuno stimulatory complexes (ISCOMs).
Pham HL; Ross BP; McGeary RP; Shaw PN; Hewavitharana AK; Davies NM
Curr Drug Deliv; 2006 Oct; 3(4):389-97. PubMed ID: 17076641
[TBL] [Abstract][Full Text] [Related]
9. Adjuvanticity and ISCOM formation by structurally diverse saponins.
Bomford R; Stapleton M; Winsor S; Beesley JE; Jessup EA; Price KR; Fenwick GR
Vaccine; 1992; 10(9):572-7. PubMed ID: 1502835
[TBL] [Abstract][Full Text] [Related]
10. Influence of Quillaja saponaria triterpenoid content on the immunomodulatory capacity of Epstein-Barr virus iscoms.
Dotsika E; Karagouni E; Sundquist B; Morein B; Morgan A; Villacres-Eriksson M
Scand J Immunol; 1997 Mar; 45(3):261-8. PubMed ID: 9122615
[TBL] [Abstract][Full Text] [Related]
11. Preparation and characterisation of quillaja saponin with less heterogeneity than Quil-A.
Kamstrup S; San Martin R; Doberti A; Grande H; Dalsgaard K
Vaccine; 2000 Apr; 18(21):2244-9. PubMed ID: 10717344
[TBL] [Abstract][Full Text] [Related]
12. Solid-phase extraction NMR studies of chromatographic fractions of saponins from Quillaja saponaria.
Nyberg NT; Baumann H; Kenne L
Anal Chem; 2003 Jan; 75(2):268-74. PubMed ID: 12553761
[TBL] [Abstract][Full Text] [Related]
13. The immunomodulating properties of human respiratory syncytial virus and immunostimulating complexes containing Quillaja saponin components QH-A, QH-C and ISCOPREP703.
Hu KF; Regner M; Siegrist CA; Lambert P; Chen M; Bengtsson KL; Morein B
FEMS Immunol Med Microbiol; 2005 Feb; 43(2):269-76. PubMed ID: 15681158
[TBL] [Abstract][Full Text] [Related]
14. Development of semisynthetic triterpenoid saponin derivatives with immune stimulating activity.
Marciani DJ; Press JB; Reynolds RC; Pathak AK; Pathak V; Gundy LE; Farmer JT; Koratich MS; May RD
Vaccine; 2000 Jul; 18(27):3141-51. PubMed ID: 10856794
[TBL] [Abstract][Full Text] [Related]
15. Immunomodulation by iscoms, immune stimulating complexes.
Morein B; Bengtsson KL
Methods; 1999 Sep; 19(1):94-102. PubMed ID: 10525444
[TBL] [Abstract][Full Text] [Related]
16. Formulation of IMXQB: Nanoparticles Based on Quillaja brasiliensis Saponins to be Used as Vaccine Adjuvants.
Rivera-Patron M; Cibulski SP; Miraballes I; Silveira F
Methods Mol Biol; 2022; 2469():183-191. PubMed ID: 35508839
[TBL] [Abstract][Full Text] [Related]
17. Iscoms containing purified Quillaja saponins upregulate both Th1-like and Th2-like immune responses.
Sjölander A; van't Land B; Lövgren Bengtsson K
Cell Immunol; 1997 Apr; 177(1):69-76. PubMed ID: 9140097
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and structure verification of the vaccine adjuvant QS-7-Api. Synthetic access to homogeneous Quillaja saponaria immunostimulants.
Deng K; Adams MM; Gin DY
J Am Chem Soc; 2008 May; 130(18):5860-1. PubMed ID: 18410100
[TBL] [Abstract][Full Text] [Related]
19. Acylated and deacylated saponins of Quillaja saponaria mixture as adjuvants for the FML-vaccine against visceral leishmaniasis.
Oliveira-Freitas E; Casas CP; Borja-Cabrera GP; Santos FN; Nico D; Souza LO; Tinoco LW; da Silva BP; Palatnik M; Parente JP; Palatnik-de-Sousa CB
Vaccine; 2006 May; 24(18):3909-20. PubMed ID: 16556475
[TBL] [Abstract][Full Text] [Related]
20. Influence of Quil A on liposomal membranes.
Paepenmüller T; Müller-Goymann CC
Int J Pharm; 2014 Nov; 475(1-2):138-46. PubMed ID: 25107288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
